Literature DB >> 10981171

Importance of various methods of blood pressure measurement in clinical trials.

P Palatini1.   

Abstract

Ambulatory blood pressure (ABP) monitoring and self-measurement of blood pressure (BP) are more reproducible than clinic BP measurement, minimize the white coat effect, and can reduce the sample size necessary to demonstrate the efficacy of a drug in clinical trials. For many years, the trough:peak ratio has been considered the key index for demonstrating the efficacy of antihypertensive agents. However, several potential problems are associated with the use of this index, and ABP monitoring makes it possible to examine changes in BP over the entire 24-hour period, not only at a preset time of peak effect and at the end of the dosing interval. The smoothness index provides more comprehensive information on the 24-hour BP control with treatment and avoids part of the problems encountered with the trough:peak ratio. One simple way to summarize the results of ABP monitoring in clinical trials is to provide the mean 24-hour BP difference from placebo and the BP decrease at trough. The numerous advantages summarized above make ABP monitoring an accepted method of BP measurement in hypertension therapy trials. Self-measurement of BP may be a valid and less expensive alternative to ABP monitoring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981171     DOI: 10.1007/s11906-000-0039-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  45 in total

1.  Benefits of ambulatory blood pressure monitoring in the design of antihypertensive drug trials.

Authors: 
Journal:  Blood Press Monit       Date:  1996-04       Impact factor: 1.444

2.  Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel.

Authors:  T Pickering
Journal:  Am J Hypertens       Date:  1996-01       Impact factor: 2.689

3.  The use of Fourier analysis in the calculation of trough to peak ratio from ambulatory blood pressure measurements.

Authors:  M Diamant; R N Idema; H H Vincent
Journal:  J Hum Hypertens       Date:  1998-01       Impact factor: 3.012

Review 4.  Calculation of trough-to-peak ratio in the research unit setting. Advantages and disadvantages.

Authors:  H L Elliott; P A Meredith
Journal:  Am J Hypertens       Date:  1996-10       Impact factor: 2.689

5.  Prognostic significance of the white coat effect.

Authors:  P Verdecchia; G Schillaci; C Borgioni; A Ciucci; C Porcellati
Journal:  Hypertension       Date:  1997-06       Impact factor: 10.190

6.  The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents.

Authors:  J Conway; J Johnston; A Coats; V Somers; P Sleight
Journal:  J Hypertens       Date:  1988-02       Impact factor: 4.844

Review 7.  Task force VI: Self-monitoring of the blood pressure.

Authors:  W B White; R Asmar; Y Imai; G A Mansoor; P Padfield; L Thijs; B Waeber
Journal:  Blood Press Monit       Date:  1999-12       Impact factor: 1.444

8.  White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study.

Authors:  P Palatini; F Dorigatti; E Roman; P Giovinazzo; D Piccolo; G De Venuto; M Mattarei; E Cozzutti; S Gregori; P Mormino; A C Pessina
Journal:  J Hypertens       Date:  1998-07       Impact factor: 4.844

9.  Evaluation of self-measured home vs. clinic intra-arterial blood pressure.

Authors:  S E Kjeldsen; A Moan; J Petrin; A B Weder; A J Zweifler; S Julius
Journal:  Blood Press       Date:  1993-03       Impact factor: 2.835

10.  Diagnosis of mild hypertension by ambulatory blood pressure monitoring.

Authors:  M A Weber; J M Neutel; D H Smith; W F Graettinger
Journal:  Circulation       Date:  1994-11       Impact factor: 29.690

View more
  1 in total

1.  Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension.

Authors:  Hans R Brunner; Klaus O Stumpe; Andrzej Januszewicz
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.